Dr. Yingji Li, CEO of ICE Bioscience, to Speak at 2023 Zhongguancun Life Science Park Innovation Summit on Biology Platforms for Challenging Drug Targets

Seizing the historic opportunities presented by the new wave of technological revolution and industrial transformation, Zhongguancun Life Science Park, as a key pillar of Beijing’s “Three Cities and One District” main platform for building an international science and technology innovation center, has invested in and constructed numerous biotechnology innovation platforms, attracting a significant influx of such entities and fostering agglomeration advantages across the upstream and downstream segments of the industry chain.On March 24, 2023, Zhongguancun Life Science Park Co., Ltd. joined forces with multiple technology platforms to co-host the “2023 Zhongguancun Life Science Park Technology Platform Industry-Research Innovation Summit.”Focusing on core themes such as “AI-empowered new drug development,” “breaking through undruggable targets,” “evaluation of biopharmaceuticals,” and “preservation and utilization of clinical biospecimens,” this initiative brings together industry leaders, investment experts, and entrepreneurs from leading and innovative enterprises. By integrating the entire industry-academia-research-application chain, it aims to promote the construction of a multi-level, broad-spectrum, functional, and open support system for novel innovation technology platforms.

Li Yingji, General Manager of Beijing iSPEAK Biotechnology Co., Ltd.Confirmed attendance at the 2023 Zhongguancun Life Science Park Technology Platform Industry-Research Innovation Summit, and will be present in the afternoon session.Innovative Drugs and Innovative Technologies Forum 2023—Breakthroughs in Undruggable Targets: “Innovative CRO + Explorer—A Drug Discovery Biology Platform Supporting Undruggable Targets”Present and share reports on the topic.

Personal Profile

Li Yingji, General Manager of Beijing Ice Bioscience Inc. He holds a Ph.D. in Science from Jilin University and a Ph.D. in Cardiovascular Medicine from the University of Giessen, Germany. He specializes in ion channel target identification, new drug screening and safety evaluation, as well as the research and development of novel therapeutics for the cardiovascular and central nervous systems. He has been honored with titles including “Distinguished Expert” under Beijing’s “Haiju Engineering” Program, “Overseas High-Level Entrepreneurial Talent” under Beijing’s “Yiqilin” Program, and “Leading Talent” under the “Xinchuang Engineering” Program of the Beijing Economic-Technological Development Area.

In 2010, Li Yingji returned to China from Austria and founded Beijing iSPEAK Biotech Co., Ltd. The company specializes in integrated biological services for innovative drug development, spanning target discovery and validation, lead compound screening and optimization, to the preclinical candidate molecule stage. It possesses mature biological and pharmacological research capabilities in therapeutic areas including oncology, immunology, cardiovascular diseases, and central nervous system disorders, and is committed to building an innovative CRO+ model.

Innovative Drugs and Innovative Technologies Forum 2023: Breaking Through Undruggable Targets

How can we leverage clinical sample analysis and proteomics to identify innovative targets with high disease relevance? How can we utilize high-resolution protein crystal structure determination platforms to assess the druggability of these targets? And how can we integrate drug design, drug screening, and multi-dimensional drug evaluation platforms to pioneer new avenues for developing therapies against challenging-to-drug targets?

This forum will explore frontier technologies and address the practical needs of the industry, providing insights into the latest technological advancements, druggable targets, new drugs, and molecular mechanisms.

Core Issues

1.Structural biology in the era of single particle cryo-EM and AI

2. ATTEC: Molecular Glue Degraders Targeting the Autophagy-Lysosome Pathway

3. Affinity Mass Spectrometry-Based Ligand Screening Targeting G Protein-Coupled Receptors

4. Applications of Cryo-Electron Microscopy in Drug Development

5. Highly Efficient and Stable TPD Proteomics Analysis Protocol

6. Innovative CRO+ Pioneer—A Drug Discovery Biology Platform Supporting Undruggable Targets

7. A Lifeline in Times of Need or Icing on the Cake—Application of Target Structure-Based Virtual Screening in New Drug Development

More topics to be confirmed. Stay tuned...

This summit is organized byGuided by the Administrative Committee of Zhongguancun Life Science Park, Zhongguancun Life Science Park Company, Zhongguancun Life Science ParkIncubator Company, Changfazhan CompanyCombinedSix Core Biotechnology Innovation Platforms: Zhongguancun AI Drug Discovery Platform, Beijing Clinical Data and Biospecimen Resource Public Service Platform, Cryo-Electron Microscopy Platform, High-Resolution Mass Spectrometry Omics Platform, Biopharmaceutical Evaluation Platform, and Integrated Biological CRO Service Platform, by focusing on core aspects of pharmaceutical R&D such as basic research, target discovery, pilot-scale development, and drug analysis, to further unlock the industry's potential, better foster the continuous growth of emerging business models, and promote high-quality development in the field of life sciences and technology.

AsThe First Grand Event Co-hosted by Zhongguancun Life Science Park and Its Technical Platforms, this summit is themed1 Main Forum + 4 Thematic Sub-forumsin a format that further ensures the depth, breadth, cutting-edge nature, and richness of resources. The main forum will serve as a central platform for showcasing the insights of industry participants, where numerous leading experts will engage in aOn Multiple Fields of Biotechnology, Including Laboratory Animals and Viral Infections"Brainstorming." The sub-forum focuses on“High-Quality Development and Sustainable Growth of Biobank Resources,” “AI-Enabled Innovative Drug R&D,” “Breakthroughs in Undruggable Targets,” and “Evaluation of Biopharmaceuticals”: Four Key DimensionsAn In-Depth Analysis of Innovation and High-Quality Development Pathways and Strategies in Biopharmaceutical Technology.

CompilationOver 40 national academicians, heads of regulatory agencies, leading academics, executives of multinational pharmaceutical companies, directors of Grade A tertiary hospitals, and seasoned investorsfeaturing renowned experts, coveringSix Major Spheres: Government, Industry, Academia, Research, Healthcare, and Investment, bringing together new ideas, new technologies, and new business models; focusing on hot issues in the industry; jointly seeking truth and insights; and conducting comprehensive, high-level, high-quality, and forward-looking sharing and discussions.

For more conference information, please scan the QR code to follow.